Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. (KKPCF) Revenue
Annual & quarterly revenue history · segment & region breakdown
KKPCF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsKaken Pharmaceutical Co., Ltd. trailing twelve-month (TTM) revenue is $77.30B, a decrease of 17.74% year-over-year from $77.35B in FY2026.
Revenue trend
2026 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $77.35B | -$16.68B | -17.74% |
| 2025-03-31 | $94.03B | +$21.99B | +30.52% |
| 2024-03-31 | $72.04B | -$0.94B | -1.29% |
| 2023-03-31 | $72.98B | -$3.05B | -4.01% |
| 2022-03-31 | $76.03B | +$1.05B | +1.41% |
| 2021-03-31 | $74.98B | -$14.26B | -15.97% |
| 2020-03-31 | $89.23B | -$4.93B | -5.24% |
| 2019-03-31 | $94.17B | -$4.26B | -4.33% |
| 2018-03-31 | $98.43B | -$3.56B | -3.49% |
| 2017-03-31 | $102B | -$7.23B | -6.62% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare KKPCF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Kaken Pharmaceutical Co., Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Kaken Pharmaceutical Co., Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in JPY.
Data sourced from Kaken Pharmaceutical Co., Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KKPCF revenue · 4 questionsKKPCF's trailing twelve-month (TTM) revenue is $77.30B. That is a decrease of 17.74% year-over-year from $77.35B in FY2026.
▸ Source: FMP · Kaken Pharmaceutical Co., Ltd. SEC filings · GAAP · Kaken Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026